- Home
- CCEL
as 10-16-2025 3:46pm EST
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | OLDSMAR |
| Market Cap: | 34.8M | IPO Year: | 1997 |
| Target Price: | $8.50 | AVG Volume (30 days): | 15.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | -0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.09 - $9.43 | Next Earning Date: | 10-15-2025 |
| Revenue: | $31,747,500 | Revenue Growth: | -0.29% |
| Revenue Growth (this year): | 1.75% | Revenue Growth (next year): | -0.05% |
Stock Insider Trading Activity of Cryo-Cell International Inc. (CCEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 18 '25 | Buy | $4.48 | 5,162 | $23,075.05 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 17 '25 | Buy | $4.43 | 5,564 | $24,648.52 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 16 '25 | Buy | $4.46 | 6,449 | $28,762.54 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 10 '25 | Buy | $4.45 | 32,317 | $143,418.51 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 9 '25 | Buy | $4.49 | 5,312 | $23,849.32 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Sep 8 '25 | Buy | $4.31 | 5,271 | $22,718.01 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Aug 27 '25 | Buy | $4.43 | 14,078 | $62,349.12 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Aug 26 '25 | Buy | $4.44 | 11,101 | $49,288.44 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Aug 25 '25 | Buy | $4.61 | 14,000 | $64,560.00 | 161,833 | |
| PORTNOY DAVID | CCEL | Chairman, Co-CEO | Aug 19 '25 | Buy | $4.37 | 885 | $3,867.45 | 161,833 |
Latest Cryo-Cell International Inc. News
CCEL Breaking Stock News: Dive into CCEL Ticker-Specific Updates for Smart Investing
Business Wire
5 months ago
Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend
TipRanks
6 months ago
Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz
Business Wire
6 months ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2025 Financial Results
Business Wire
9 months ago
Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives
Business Wire
a year ago
Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend
Business Wire
a year ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
Business Wire
a year ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results
GOBankingRates
a year ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
Compare CCEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CCEL Cryo-Cell International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.